DSDaniela Dottore Stagna

Daniela Dottore Stagna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Daniela Dottore Stagna has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 19 November 2026
    • Published by MDPI AG in Preprints.org
      • https://doi.org/10.20944/preprints202611.2011.v1
    Open Access

    Improved Diagnostic Yield in Mitochondrial Diseases: A Single-Center Experience Following the Validation and Clinical Implementation of a Joint MITO-NUCLEAR Next-Generation Sequencing Panel

    by Fabiana Uomo, Chiara De Falco, Ferdinando Barretta, Nancy Messina, Rosa Redenta De Simone, Daniela Dottore Stagna, Antonia Pascarella, Enza Mozzillo, Dario Iafusco, Giulia Frisso, et al.

    Background/Objectives: Mitochondrial diseases (MDs) are heterogeneous genetic disorders caused by oxidative phosphorylation impairment, governed by both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). Traditional multi-step diagnostic strategies, involving mtDNA long-range PCR and screening of a limited set of nuclear genes, often leave many patients without a molecular diagnosis. This study evaluates the clinical implementation of a single-step MITO-NUCLEAR Next-Generation (NGS) panel (whole mtDNA and 254 nuclear genes), previously developed and validated by our group. Methods: Buccal swab DNA from 70 patients with suspected MDs was sequenced using an optimized probe dilution ratio (1:500, mtDNA: nDNA), achieving mean depths of ~10,000× (mtDNA) and 110× (nDNA). Variants were classified according to ACMG/AMP guidelines and their mtDNA-specific specifications. Results: Ninety unique variants were identified (86.7% nuclear). A definitive molecular diagnosis was reached in 17% of patients, compared with 5.7% for mtDNA analysis alone: four primary mtDNA defects (MT-TS1, MT-CYB, MT-TL1, MT-ATP6), two nuclear-encoded mitochondrial disorders (ECHS1, FH) and six non-mitochondrial phenocopies (WFS1, ATP7B, G6PC1, ABCA4, KIF1A). A possible diagnosis was reached in 20% of patients, 46% were carriers of monoallelic variants in recessive genes, and 17% were negative. Conclusions: Simultaneous MITO-NUCLEAR NGS testing significantly increases diagnostic yield over single-genome screening. This single-step targeted panel offers a fast and efficient tool that facilitates variant identification across both genomes, supporting accurate clinical management and timely familial genetic counseling.